Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, Yancy et al lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312 8. 131. Pfeffer MA, Braunwald E, Moy LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocar- dial infarction: results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992;327:669 77. 132. Effect of ramipril on mortality and morbidity of survivors of acute myocar- dial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821 8. 133. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the an- giotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670 6. 134. Cohn JN, Tognoni G, Investigators VHFT. A randomized trial of the angio- tensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667 75. 135. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893 906. 136. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose ver- sus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374: 1840 8. 137. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759 66. 138. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibi- tion versus enalapril in heart failure. N Engl J Med. 2014;371:993 1004. 139. 